Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis
Immunity, Inflammation and Disease · 2024-07 · 12 (7)
DOI: 10.1002/iid3.1356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 29.07.2024. Verfasst von Luping Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Signal Transduction, Toll-Like Receptors, Homeostasis. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Scholarship Council, National Natural Science Foundation of China, Open Project of Translational Chinese Medicine Key Laboratory of Sichuan Province.
Abstract (Originalsprache)
Background
Toll‐like receptors (TLRs) are a family of fundamental pattern recognition receptors in the innate immune system, constituting the first line of defense against endogenous and exogenous antigens. The gut microbiota, a collection of commensal microorganisms in the intestine, is a major source of exogenous antigens. The components and metabolites of the gut microbiota interact with specific TLRs to contribute to whole‐body immune and metabolic homeostasis.
Objective
This review aims to summarize the interaction between the gut microbiota and TLR signaling pathways and to enumerate the role of microbiota dysbiosis‐induced TLR signaling pathways in obesity, inflammatory bowel disease (IBD), and colorectal cancer (CRC).
Results
Through the recognition of TLRs, the microbiota facilitates the development of both the innate and adaptive immune systems, while the immune system monitors dynamic changes in the commensal bacteria to maintain the balance of the host‐microorganism symbiosis. Dysbiosis of the gut microbiota can induce a cascade of inflammatory and metabolic responses mediated by TLR signaling pathways, potentially resulting in various metabolic and inflammatory diseases.
Conclusion
Understanding the crosstalk between TLRs and the gut microbiota contributes to potential therapeutic applications in related diseases, offering new avenues for treatment strategies in conditions like obesity, IBD, and CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Pharmacology and Toxicology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
- Oxford Suzhou Centre for Advanced Research, Suzhou, China.
- Sichuan Institute for Translational Chinese Medicine, Chengdu, China.
- Sichuan Academy of Chinese Medical Sciences, Chengdu, China.
- Global R&D Innovation Center, Inner Mongolia Mengniu Dairy (Group) Co. Ltd., Hohhot, Inner Mongolia, China.
ORCID-Profile: Luping Chen, Ruirui Wang
Förderung
- Chinese Scholarship Council
- National Natural Science Foundation of China
- Open Project of Translational Chinese Medicine Key Laboratory of Sichuan Province
Zitieren
APA
Chen, L., Zhang, L., Hua, H., Liu, L., Mao, Y., & Wang, R. (2024). Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis. Immunity, Inflammation and Disease, 12(7). https://doi.org/10.1002/iid3.1356
Vancouver
Chen L, Zhang L, Hua H, Liu L, Mao Y, Wang R. Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis. Immunity, Inflammation and Disease. 2024;12(7). doi:10.1002/iid3.1356
BibTeX
@article{Chen2024,
author = {Chen, Luping and Zhang, Linfang and Hua, Hua and Liu, Li and Mao, Yuejian and Wang, Ruirui},
title = {Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis},
journal = {Immunity, Inflammation and Disease},
year = {2024},
volume = {12},
number = {7},
doi = {10.1002/iid3.1356}
}
EUVIMED